Equities

Beyond Air Inc

Beyond Air Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)0.40
  • Today's Change0.018 / 4.68%
  • Shares traded336.75k
  • 1 Year change-85.87%
  • Beta-0.1126
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received United States Food and Drug Administration (FDA) approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. It is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19), and nontuberculous mycobacteria (NTM) among others. It has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder (ASD) and other neurological disorders. Its approved product and active pipeline of product candidates include LungFit PH, LungFit PRO and LungFit GO.

  • Revenue in USD (TTM)1.78m
  • Net income in USD-58.35m
  • Incorporated2015
  • Employees107.00
  • Location
    Beyond Air Inc900 STEWART AVENUE, SUITE 301GARDEN CITY 11530United StatesUSA
  • Phone+1 (516) 665-8200
  • Websitehttps://www.beyondair.net/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Applied DNA Sciences Inc3.40m-7.52m12.46m53.00--1.01--3.67-11.86-11.862.181.200.20926.835.6864,114.15-45.51-88.57-55.20-121.9125.0444.35-217.48-113.263.76--0.00---26.4327.92-18.73--33.80--
QT Imaging Holdings Inc0.00-4.02m12.86m----0.5917-----0.3999-0.39990.001.010.00-------12.32---16.60--------------0.3042-------45.07------
Vapotherm Inc70.92m-54.42m13.55m182.00------0.1911-8.50-8.5011.08-13.030.89771.568.11389,664.80-68.88-49.73---62.5446.7443.56-76.74-78.990.0934-1.063.19--2.8010.1448.62---10.38--
REMSleep Holdings Inc144.88k-1.81m14.41m6.00--25.06--99.46-0.0012-0.00120.00010.00040.081.694.75---99.82-152.40-122.32-317.98-491.08---1,246.94-2,317.521.47-43.580.1207---36.48--12.13--28.26--
Trinity Biotech plc (ADR)58.65m-22.29m14.55m380.00------0.2482-2.74-2.747.23-19.240.70521.693.74154,347.40-26.80-20.30-35.44-29.5434.2839.92-38.01-29.860.8936-2.161.46---9.10-10.1515.41---31.08--
Autonomix Medical Inc-100.00bn-100.00bn15.01m5.00--2.37----------0.2749----------------------------0.1647-------674.99------
LiveCare Inc0.00-2.34m15.26m----6.47-----0.1411-0.14110.000.04630.00-------424.83---550.62-------------8.180.1888-------344.86------
Cutera Inc169.19m-148.97m15.50m430.00------0.0916-7.46-7.468.46-10.730.45722.083.86393,460.50-40.25-22.00-51.64-30.728.1847.63-88.05-27.242.17-31.342.05---15.865.47-97.76--85.87--
Innovative Eyewear Inc1.53m-7.86m15.53m11.00--2.06--10.15-11.01-11.012.054.810.17791.9715.91139,070.90-91.45---96.06---2.46---514.10--12.85--0.00--74.67---17.28------
BioRegenx Inc634.81k-727.95k17.12m10.00--1.01--26.97-0.001-0.0010.00160.01780.0617----63,481.00-7.07---8.46--74.90---114.67--0.1547-8.800.0977---47.25---629.37------
PAVmed Inc3.83m-67.35m17.17m107.00------4.48-8.17-8.170.4595-7.740.0823--29.4535,785.05-155.93-154.56---1,152.82-77.59---1,895.64-8,764.890.5529-8.161.74--550.40--25.76--55.51--
Beyond Air Inc1.78m-58.35m17.78m107.00--1.09--9.97-1.65-1.650.04850.35140.02981.706.8716,663.55-104.22-78.25-137.64-99.91-78.30---3,493.78-6,152.992.42-38.110.4666-----31.57-7.93--152.05--
Spectral AI Inc22.53m-20.24m19.01m78.00------0.8439-1.48-1.481.55-0.24221.68--11.54288,859.00-150.54---954.46--45.12---89.85--0.7066--2.14---28.82---616.14------
Neuraxis Inc2.27m-15.26m20.05m19.00------8.84-3.09-3.090.4039-0.76861.096.6311.80119,318.90-731.17------87.29---672.94--0.2724-19.01-----8.37---163.78------
SeaStar Medical Holding Corp0.00-33.23m20.79m12.00---------21.41-21.410.00-2.140.00----0.00-1,145.80-----------------9.51---------115.19------
Data as of Sep 20 2024. Currency figures normalised to Beyond Air Inc's reporting currency: US Dollar USD

Institutional shareholders

21.93%Per cent of shares held by top holders
HolderShares% Held
AIGH Capital Management LLCas of 30 Jun 20243.64m7.82%
Kingdon Capital Management LLCas of 30 Jun 20241.36m2.92%
The Vanguard Group, Inc.as of 30 Jun 20241.25m2.70%
Adar1 Capital Management LLCas of 30 Jun 20241.23m2.63%
Rosalind Advisors, Inc.as of 30 Jun 2024903.61k1.94%
BlackRock Fund Advisorsas of 30 Jun 2024514.17k1.11%
DWS Investment Management Americas, Inc.as of 30 Jun 2024403.25k0.87%
Geode Capital Management LLCas of 30 Jun 2024345.63k0.74%
Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 2024303.11k0.65%
Wealth Effects LLCas of 30 Jun 2024256.30k0.55%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.